Hemolytic-uremic syndrome medical therapy

Revision as of 13:16, 21 September 2012 by Shankar Kumar (talk | contribs) (Created page with "__NOTOC__ {{HUS}} {{CMG}} ==Overview== ==Medical Therapy== Treatment is generally supportive with dialysis as needed. Platelet transfusion may a...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Hemolytic-uremic syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemolytic-uremic syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemolytic-uremic syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemolytic-uremic syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemolytic-uremic syndrome medical therapy

CDC on Hemolytic-uremic syndrome medical therapy

Hemolytic-uremic syndrome medical therapy in the news

Blogs on Hemolytic-uremic syndrome medical therapy

Directions to Hospitals Treating Hemolytic-uremic syndrome

Risk calculators and risk factors for Hemolytic-uremic syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

Treatment is generally supportive with dialysis as needed. Platelet transfusion may actually worsen outcome.

In severe cases or when there is diagnostic uncertainty between HUS and TTP, plasmapheresis is the treatment of choice.

Antibiotic treatment of O157:H7 colitis may stimulate further verotoxin production and thereby increase the risk of HUS.[1]

  • Plasma exchange daily until LDH normal and platelets stable
  • Renal pathology may not entirely resolve (no data on continued plasma exchange after platelets and markers of hemolysis have resolved)
  • Average 7-16 exchanges required to induce remission
  • Caution plasmapheresis-associated thrombocytopenia (more with certain instruments)
  • Cryopoor plasma exchange not better than regular FFP

References

Template:WH Template:WS